Amgen escalates PCSK9 pricing war with permanent 60% price cut on Repatha

25th October 2019 Uncategorised 0

Amgen cut the list price of its PCSK9 cholesterol drug Repatha from $14,520 to $5,850 last year but maintained the pricier option for insurers who preferred to take it, along with what were likely steep discounts. Now, Amgen is doing away with the high-priced version of the product. But will that be enough to boost demand?

More: Amgen escalates PCSK9 pricing war with permanent 60% price cut on Repatha
Source: fierce